Read twice and referred to the Committee on Finance.
This bill (Open Payments Expansion Act) amends section 1128G of the Social Security Act to require applicable pharmaceutical manufacturers and applicable group purchasing organizations to report, annually, covered payments made to patient advocacy organizations. Beginning March 31, 2027 and each year thereafter, manufacturers and GPOs must submit electronically to the Secretary the name of the patient advocacy organization and the amount of each covered payment, including indirect payments made through third parties where the manufacturer or GPO caused the transfer.
Transparency vs. chilling philanthropy: liberals emphasize disclosure and accountability; conservatives worry disclosure will deter donations and burden civil society.
Relative to its intended legislative type, this bill is a focused statutory expansion of existing Open Payments reporting to cover patient advocacy organizations.
This bill (Open Payments Expansion Act) amends section 1128G of the Social Security Act to require applicable pharmaceutical manufacturers and applicable group purchasing organizations to report, annually, covered payments made to patient advocacy organizations.
Beginning March 31, 2027 and each year thereafter, manufacturers and GPOs must submit electronically to the Secretary the name of the patient advocacy organization and the amount of each covered payment, including indirect payments made through third parties where the manufacturer or GPO caused the transfer.
The bill defines covered payment, indirect payment, and patient advocacy organization (limited to entities described in section 501(c)(3) and exempt under section 501(a) of the Internal Revenue Code with specified patient-oriented missions).
On content alone, the bill is a modest, administratively focused expansion of an existing transparency program with no new spending and clear definitions, which tends to improve prospects. Key countervailing factors include predictable industry resistance to expanded disclosure of payments to patient groups, potential pushback from affected nonprofit organizations, and possible legal or procedural objections to the Paperwork Reduction Act exemption. Taken together, these produce a moderate likelihood of enactment absent other political context.
Relative to its intended legislative type, this bill is a focused statutory expansion of existing Open Payments reporting to cover patient advocacy organizations. It clearly states its purpose, integrates into the current statutory framework, and sets basic reporting requirements and definitions.
Transparency vs. chilling philanthropy: liberals emphasize disclosure and accountability; conservatives worry disclosure will deter donations and burden civil society.
These are examples from the analysis, not a ranked list of the most-affected groups.
Transparency vs. chilling philanthropy: liberals emphasize disclosure and accountability; conservatives worry disclosure will deter donations and burden civil society.
A mainstream liberal/left-leaning observer would view the bill largely positively as an expansion of transparency around pharmaceutical industry influence.
They would see bringing patient advocacy organizations into the Open Payments framework as a sensible step to reveal potential conflicts of interest and commercial influence on groups that shape patient views and policy.
However, they may note the bill’s reporting scope (only name and amount) is narrower than ideal and could press for more detail on purpose and use of funds.
A centrist/moderate observer would generally favor increased transparency but would be attentive to the bill’s design details and implementation costs.
They would appreciate extending an established disclosure regime to patient advocacy groups to reduce hidden influence, while wanting clarity on administrative burden, reporting format, compliance costs for industry and small nonprofits, and whether the disclosures will be actionable.
They would likely view the Paperwork Reduction Act exemption with concern as it bypasses a standard review of reporting burdens.
A mainstream conservative observer would be skeptical of expanding federal disclosure mandates and likely view the bill as an added regulatory and compliance burden on businesses and potentially on civil society.
They would be concerned that public disclosure of donations could chill charitable giving and free association, or subject nonprofits to politicized scrutiny.
Some conservatives who prioritize government transparency might see limited merit, but many would object to the PRA exemption and to extending federal reporting into private charitable relationships without clearer justification and safeguards.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, the bill is a modest, administratively focused expansion of an existing transparency program with no new spending and clear definitions, which tends to improve prospects. Key countervailing factors include predictable industry resistance to expanded disclosure of payments to patient groups, potential pushback from affected nonprofit organizations, and possible legal or procedural objections to the Paperwork Reduction Act exemption. Taken together, these produce a moderate likelihood of enactment absent other political context.
The bill has not accumulated any surfaced votes yet.
Transparency vs. chilling philanthropy: liberals emphasize disclosure and accountability; conservatives worry disclosure will deter donatio…
On content alone, the bill is a modest, administratively focused expansion of an existing transparency program with no new spending and cle…
Relative to its intended legislative type, this bill is a focused statutory expansion of existing Open Payments reporting to cover patient advocacy organizations. It clearly states its purpose, integrates into the curre…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.